Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 26Leukemia, Lymphocytic, Chronic, B-Cell 24Neoplasms 8Leukemia 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Chromosome 17 deletion 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Leukemia, B-Cell 2Venentoclax 1Tumor Lysis Syndrome 1Pathologic Complete Response 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Allopurinol 2venetoclax 1rasburicase 1obinutuzumab 1Urate Oxidase 1Febuxostat 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Tumor Lysis Syndrome × venetoclax × Clear all
NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie

Phase 3 Completed
120 enrolled 14 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡